Yes, but you have to remember that these are Medicare data. The prevalence of 65+ patients getting Her2+ breast cancer AND getting treatment with Herceptin is

Yes, but you have to remember that these are Medicare data. The prevalence of 65+ patients getting Her2+ breast cancer AND getting treatment with Herceptin is probably lower than the number of 65+ patients getting ARMD and going on treatment with Lucentis. Unfortunately, I don't have a good source. The above is merely my speculation.